Compare MXE & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXE | ICCC |
|---|---|---|
| Founded | 1990 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.4M | 55.5M |
| IPO Year | 1994 | 1995 |
| Metric | MXE | ICCC |
|---|---|---|
| Price | $13.11 | $6.54 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.3K | ★ 12.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $32.15 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $8.26 | $4.32 |
| 52 Week High | $14.30 | $7.60 |
| Indicator | MXE | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 53.29 |
| Support Level | $13.07 | $6.13 |
| Resistance Level | $14.30 | $6.87 |
| Average True Range (ATR) | 0.30 | 0.24 |
| MACD | -0.17 | -0.01 |
| Stochastic Oscillator | 45.41 | 68.57 |
Mexico Equity and Income Fund Inc. is a closed-end, non-diversified management investment company that aims for long-term capital appreciation and current income. It prominently invests in equity, convertible securities, and debt issued by Mexican companies, operating across various sectors. The fund benchmarks its performance against the Mexbol and MSCI Mexico Index. The company provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.